Home › Trial NCT02939014
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
- Trial IDNCT02939014
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorTakeda
- Enrollment39
- Start date2016-11-07
- ConditionsHodgkin Disease · Lymphoma, Large-Cell, Anaplastic
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.